CD-388 is under clinical development by Cidara Therapeutics and currently in Phase II for Pandemic Influenza. According to GlobalData, Phase II drugs for Pandemic Influenza does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the CD-388 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CD-388 overview

CD-388 is under development for the treatment and prevention of influenzavirus A, seasonal influenza, pandemic influenza and influenzavirus B infections. The drug candidate is a second generation, anti-viral Fc conjugate (AVC). It comprises of two moieties attached through a chemical linker. One is a targeting moiety (TM) that recognizes cell surface target and another is an effector moiety (EM) that is recognized by the immune system. The drug candidate is developed based on the cloudbreak platform. It is administered through intramuscular and subcutaneous route.

Cidara Therapeutics overview

Cidara Therapeutics (Cidara) formerly K2 Therapeutics is a biotechnology company. The company discovers, develops and commercializes novel anti-infectives including immunotherapies. Its pipeline products include rezafungin for the treatment of invasive fungal disease and CD388 for treating influenza. Cidara is investigating RSV AVC program for the treatment of respiratory syncytial virus (RSV), HIV AVC for human immunodeficiency viruses (HIV), CoV AVC for pan coronavirus. The company’s proprietary Cloudbreak, an antiviral platform for the fight against life-threatening infectious diseases that provides potent antiviral activity and immune system engagement in a single molecule. Cidara is headquartered in San Diego, California, the US.

For a complete picture of CD-388’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.